Fertility Treatments: IUI, IVF, and ICSI Basics

Common options

Intrauterine insemination (IUI) places prepared sperm directly into the uterus around ovulation and is often a first step for mild factors. In vitro fertilization (IVF) combines eggs and sperm in a lab, then transfers an embryo to the uterus.

Intracytoplasmic sperm injection (ICSI) injects a single sperm into an egg and is used mainly for male-factor infertility. Treatment choice depends on diagnosis, age, and prior results.

What to expect

Success rates depend strongly on age and underlying cause. Treatments involve monitoring, hormonal medication, and sometimes multiple cycles. Emotional support and realistic counseling are an important part of care.

How the main treatments differ

Assisted reproduction spans a range of options. IUI (intrauterine insemination) places prepared sperm directly into the uterus around ovulation and is less invasive and lower cost. IVF (in vitro fertilization) retrieves eggs, fertilizes them in a laboratory, and transfers an embryo to the uterus. ICSI, often used with IVF, injects a single sperm into an egg and helps with certain sperm-related issues.

Setting realistic expectations

Success rates depend heavily on age, the cause of infertility, and individual factors, and treatment can be emotionally and financially demanding. Multiple cycles are sometimes needed. A fertility specialist can recommend the most suitable approach and explain likely outcomes, and counseling support is valuable throughout the process.

When Fertility Treatment Becomes the Next Step

Fertility treatment encompasses a spectrum of interventions — from relatively simple procedures like intrauterine insemination (IUI) to the more complex technology of in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI). The step toward treatment is often preceded by a structured period of investigation that identifies the underlying cause of difficulty conceiving. The cause — whether tubal occlusion, anovulation, male factor, unexplained infertility, or a combination — guides which treatment is most appropriate and most likely to be cost-effective.

It is important to understand from the outset that these treatments assist reproduction — they do not guarantee it. Success rates vary significantly by age, diagnosis, clinic quality, and the number of cycles attempted. Informed decision-making depends on realistic success estimates relevant to your specific circumstances, not population averages or clinic headline figures. Asking a clinic for their age-stratified live birth rates per egg collection — the most clinically meaningful metric — is a reasonable and appropriate question.

IUI: Intrauterine Insemination Explained

IUI is the simplest form of assisted reproduction. It involves placing washed, concentrated sperm directly into the uterine cavity through a thin catheter around the time of ovulation. The procedure is brief, usually painless, and performed in a clinic without anaesthesia. Washing the sperm sample separates motile sperm from seminal fluid and other cells, increasing the concentration delivered to the uterus and reducing the risk of uterine cramping from prostaglandins in the semen.

IUI is most suitable when sperm parameters are mildly reduced but not severely so, when cervical mucus is hostile to sperm (rare), in cases of unexplained infertility, or for single women and same-sex female couples using donor sperm. It is generally not effective when tubes are blocked, when severe male factor infertility is present, or when ovarian reserve is very low. IUI can be performed in natural cycles (tracking spontaneous ovulation) or stimulated cycles (using low-dose fertility medications to produce one or two follicles), the latter modestly improving success rates but also slightly increasing the risk of multiple pregnancy.

Per-cycle success rates for IUI with mild male factor or unexplained infertility are typically in the range of 10–20% live birth per cycle, depending on age and diagnosis. Most clinicians recommend a maximum of three to six IUI cycles before moving to IVF if pregnancy has not occurred, as success rates decline after multiple failed IUI attempts and continued delay can matter when age is a factor.

IVF: The Process Step by Step

IVF begins with ovarian stimulation — daily injectable gonadotrophins (follicle-stimulating hormone, with or without luteinising hormone) administered subcutaneously at home for 10–14 days. These medications stimulate multiple follicles to develop simultaneously. Progress is monitored by transvaginal ultrasound scans (typically two to four during the stimulation phase) and sometimes blood oestrogen measurements to assess response and prevent dangerous overstimulation.

When the leading follicles reach approximately 17–20 mm in diameter, a trigger injection (usually hCG or a GnRH agonist) initiates final egg maturation. Egg collection takes place 35–36 hours later, typically under light sedation. A fine needle is passed through the vaginal wall under ultrasound guidance into each follicle to aspirate the follicular fluid containing the egg. The eggs are identified under a microscope by an embryologist and placed in culture medium in an incubator designed to mimic the conditions of the fallopian tube.

Fertilisation is then achieved by either conventional insemination (adding prepared sperm to the dish with the egg and allowing natural penetration) or ICSI (see below). Fertilised eggs are cultured for three to five days; blastocyst-stage embryos at day five are generally preferred for transfer as they have demonstrated developmental competence. One or two embryos are selected for transfer to the uterus via a thin catheter — a procedure similar to IUI and typically painless. Remaining suitable embryos can be vitrified (frozen) for future use.

ICSI: When and Why It Is Used

Intracytoplasmic sperm injection is a micromanipulation technique in which a single sperm is selected, immobilised, and injected directly into the cytoplasm of a mature egg using a fine glass needle under high-powered microscopy. ICSI bypasses all the natural barriers to fertilisation — it does not require the sperm to penetrate the zona pellucida or the egg membrane under its own power. This makes it the treatment of choice when sperm count, motility, or morphology is severely compromised, when there is a previous history of very poor or total fertilisation failure with conventional IVF, or when sperm has been surgically retrieved from the epididymis or testes.

ICSI has been adopted very widely — in some countries it is used in the majority of IVF cycles regardless of sperm quality — but the evidence does not support its routine use when semen parameters are normal. Fertilisation rates with ICSI are typically 60–80% of injected mature eggs. The procedure does carry a small risk of egg damage during injection (typically 5–10%), and there is an ongoing scientific discussion about whether ICSI bypasses natural sperm selection processes in ways that could marginally increase the rate of certain genetic conditions in offspring — though current data are largely reassuring.

Understanding Success Rates and Realistic Expectations

IVF success rates vary primarily by the woman's age at egg collection. Approximate cumulative live birth rates per egg collection cycle in the UK (HFEA data) are roughly 30–35% for women under 35, falling to around 20–25% at 35–37, 15–20% at 38–39, and progressively lower thereafter. These rates reflect a single egg collection that may result in a fresh transfer and subsequent frozen transfers from the same cohort of embryos — the cumulative figure is more meaningful than a per-transfer rate.

When assessing a clinic's results, ask specifically for their live birth rate per egg collection for your age group, not their pregnancy rate (which includes biochemical pregnancies that do not continue) or their implantation rate. Clinic league tables can be misleading because clinics that offer treatment to older women or poorer prognosis patients will have lower headline rates due to case mix, not poorer quality of care. Regulatory bodies such as the HFEA in the UK publish clinic-by-clinic data that allows direct comparison.

Risks, Side Effects, and Complications

The most significant medical complication of IVF stimulation is ovarian hyperstimulation syndrome (OHSS), which occurs when the ovaries respond excessively to stimulation medications. Mild OHSS — bloating, abdominal discomfort, nausea — is common and self-limiting. Moderate to severe OHSS involves significant fluid accumulation, vomiting, shortness of breath, and in rare cases, blood clots or kidney complications. Risk factors include high AMH, young age, PCOS, and high egg numbers at retrieval. The widespread shift to GnRH antagonist protocols and the use of GnRH agonist triggers in high-responders has dramatically reduced the incidence of severe OHSS.

Multiple pregnancy — twins or higher-order multiples — was historically a major IVF complication when two or more embryos were routinely transferred. The shift toward single embryo transfer (SET) in most countries has dramatically reduced this risk. SET in good-prognosis patients preserves live birth rates comparable to double transfer while almost eliminating the risks associated with twin pregnancy (preterm birth, low birthweight, maternal complications). Embryo banking strategies — accumulating embryos over several egg collections before transfer — make SET increasingly viable for a wider range of patients.

Emotional and Financial Dimensions of Treatment

Fertility treatment is psychologically demanding. The combination of hope, uncertainty, physical discomfort from injections and procedures, and the grief of failed cycles creates significant emotional strain. Research consistently shows that women undergoing fertility treatment report stress levels comparable to patients managing serious chronic illness. Psychological support — whether through clinic-provided counselling, support groups, or private therapy — is not a luxury; it improves both wellbeing and, in some studies, treatment outcomes.

Financially, IVF is a substantial investment in countries without universal public funding. In the UK, NHS funding is available in some areas for eligible patients, but provision is highly inconsistent. Privately, a single IVF cycle including monitoring, medications, and transfer typically costs £4,000–£7,000. Packages offering multiple cycles can reduce per-cycle cost but require careful scrutiny of what is and is not included, and what refund policies apply if you discontinue treatment. Seek clear written cost breakdowns before committing.

Frequently Asked Questions

Q: Is IVF painful? A: The daily injections cause mild discomfort similar to an insulin injection — most people adapt quickly. The egg collection procedure is performed under light sedation or anaesthesia and is typically not painful during the procedure; some women experience cramping and bloating for a day or two afterward. The embryo transfer is usually no more uncomfortable than a cervical smear test.

Q: How many cycles should we try before stopping? A: This is deeply personal and depends on prognosis, finances, and emotional reserves. Cumulative success rates improve over multiple cycles up to approximately three to four egg collections. Beyond that, the incremental benefit diminishes, though some women do succeed after more attempts. Clinics should offer a clear prognosis review after each cycle — if the expected success rate per additional cycle is very low, continuing treatment should be a genuinely informed choice rather than a default.

Q: Can we choose the sex of our baby through IVF? A: Sex selection for non-medical reasons is not permitted in the UK and many other countries. Pre-implantation genetic testing for aneuploidy (PGT-A), which is used to identify chromosomally normal embryos, does reveal the sex of each embryo, but clinics bound by regulatory guidelines transfer based on chromosomal normality, not sex, unless there is a specific sex-linked medical condition.

Q: Does IVF increase the risk of cancer? A: Large epidemiological studies to date have not demonstrated a significant increase in breast, ovarian, or endometrial cancer risk attributable to IVF treatment specifically. Women with fertility problems may have modestly elevated background cancer risk compared to fertile women (partly due to shared hormonal influences), but IVF stimulation itself has not been identified as an independent carcinogen. The research continues and is appropriately monitored.